FrancophonIA/ELRC3.0 huggingface dataset:
English: The European Medicines Agency decided that Tamiflu's benefits are greater than its risks and recommended that it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Tamiflu kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Effectiveness was measured by recording symptoms (feeling feverish, muscle pain, headache, sore throat, cough, overall discomfort and runny nose).
Estonian: Efektiivsuse määramiseks registreeriti sümptomid (palavikutunne, lihasevalu, peavalu, kurguvalu, köha, üldine ebamugavustunne ja ninavoolus).
English: For adults with a weakened immune system (the body's natural defences), it is given for 10 days.
Estonian: Nõrgenenud immuunsüsteemiga (organismi looduslikud kaitsemehhanismid) täiskasvanutele manustatakse ravimit 10 päeva.
English: Other information about Tamiflu
Estonian: Muu teave Tamiflu kohta
English: Tamiflu can also be used as preventative treatment in exceptional cases, for instance when the seasonal flu vaccine may not provide sufficient protection and when there is a pandemic (a global epidemic of flu).
Estonian: Tamiflud tohib kasutada erandkorras ka ennetusraviks, näiteks kui hooajaline gripivaktsiin ei taga piisavat kaitset ja kui esineb gripipandeemia (ülemaailmne gripiepideemia).
English: It can also reduce the incidence of flu in patients who had come into contact with the disease or during a pandemic.
Estonian: See võib vähendada ka grippi haigestumist haigusega kokku puutunud patsientidel või pandeemia ajal.
English: The medicine contains the active substance oseltamivir.
Estonian: Ravim sisaldab toimeainena oseltamiviiri.
English: Tamiflu is available as capsules (30 mg, 45 mg, and 75 mg) and as a powder that is made up into a liquid to be drunk (6 mg/ml and 12 mg/ml).
Estonian: Tamiflud turustatakse kapslitena (30 mg, 45 mg ja 75 mg) ja lahustuva joogipulbrina (6 mg/ml ja 12 mg/ml).
English: Tamiflu reduced the incidence of flu in people who had come into contact with the disease when one of their family members contracted flu (962 cases) or during an epidemic (1,562 people aged between 16 and 65 years, and 548 elderly people in nursing homes).
Estonian: Tamiflu vähendas grippi haigestumist haigusega kokkupuutes olnud isikutel, kelle üks perekonnaliige oli nakatunud grippi (962 juhul), või epideemia korral (1562 isikut vanuses 16-65-aastat ning 548 eakat hooldekodudes).
English: As for all medicines, data on the use of Tamiflu are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Tamiflu kasutamise kohta pidevat järelevalvet.
English: What is Tamiflu and what it is used for?
Estonian: Mis on Tamiflu ja milleks seda kasutatakse?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tamiflu have been included in the summary of product characteristics and the package leaflet.
Estonian: Tamiflu ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Side effects reported with Tamiflu are carefully evaluated and any necessary action taken to protect patients.
Estonian: Tamiflu kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Oseltamivir works on the neuramidases of both influenza A (the most common type) and influenza B viruses.
Estonian: Oseltamiviir toimib A-tüüpi gripiviiruse (kõige tavalisem tüüp) ning B-tüüpi gripiviiruse neuraminidaasidele.
English: A study also looked at using Tamiflu in a family setting (277 families) for both the treatment of the person with flu, and the treatment or prevention of flu in those in contact with the person.
Estonian: Ühes uuringus vaadeldi ka Tamiflu kasutamist perekonna tingimustes (277 perekonda) gripipatsiendi raviks ning gripi raviks või ennetamiseks gripipatsiendiga kokkupuutes olnud isikutel.
English: For more information about using Tamiflu, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Tamiflu kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Tamiflu is an antiviral medicine used to treat or prevent influenza (flu).
Estonian: Tamiflu on viirusvastane ravim, mida kasutatakse gripi raviks või ennetamiseks.
English: The usual dose for adults and children weighing more than 40 kg is 75 mg given once a day for at least 10 days after contact with an infected person.
Estonian: Täiskasvanutel ja üle 40 kg kaaluvatel lastel on tavaannus 75 mg, mida manustatakse 1 kord ööpäevas vähemalt 10 päeva jooksul pärast kokkupuudet nakatunud isikuga.
English: When Tamiflu is used during a flu epidemic, it is given for up to 6 weeks.
Estonian: Kui Tamiflud kasutatakse gripiepideemia ajal, tohib seda annust kasutada kuni 6 nädala jooksul.
English: For the full list of side effects and restrictions with Tamiflu, see the package leaflet.
Estonian: Tamiflu kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The usual dose for adults and children weighing more than 40 kg is 75 mg given twice a day for 5 days.
Estonian: Täiskasvanutel ja üle 40 kg kaaluvatel lastel on tavaannus 75 mg, mida manustatakse 2 korda ööpäevas 5 päeva jooksul.
English: What are the risks associated with Tamiflu?
Estonian: Mis riskid Tamifluga kaasnevad?
English: In adults, the duration of the illness was reduced from an average of 5.2 days for patients taking placebo, to 4.2 days for patients taking Tamiflu.
Estonian: Täiskasvanutel vähenes haiguse kestus platseeborühma patsientide keskmiselt 5,2 päeva Tamiflud võtnud patsientide 4,2 päevani.
English: The active substance in Tamiflu, oseltamivir, acts on the flu virus, blocking some of the enzymes on its surface known as neuramidases.
Estonian: Tamiflu toimeaine oseltamiviir toimib spetsiifiliselt gripiviirusele, blokeerides teatud ensüümid (neuraminidaasid) viiruse pinnal.
English: How does Tamiflu work?
Estonian: Kuidas Tamiflu toimib?
English: In the treatment of flu, Tamiflu must be started within two days of the onset of symptoms.
Estonian: Gripi ravimisel peab Tamiflu kasutamist alustama 2 ööpäeva jooksul alates sümptomite tekkest.
English: When used for treatment of flu, Tamiflu reduces the duration of illness in adults and children.
Estonian: Gripi ravimisel vähendab Tamiflu täiskasvanutel ja lastel haiguse kestust.
English: • to treat flu, it can be used in adults and children (including full-term newborns) who have the symptoms of flu, when the flu virus is circulating in the community;
Estonian: • Gripi raviks tohib ravimit kasutada gripisümptomitega täiskasvanutel ja lastel (sh õigeaegsetel vastsündinutel), kui kogukonnas levib gripiviirus.
English: During a flu pandemic, Tamiflu can also be used to prevent flu in babies below 1 year of age.
Estonian: Gripipandeemia ajal tohib Tamiflud kasutada gripi raviks või ennetamiseks ka alla 1-aastastel imikutel.
English: In families with one patient who had flu, 7% of the family members in the household developed flu when receiving Tamiflu, compared with 20% of those receiving no preventative treatment.
Estonian: Perekondades, kus ühel patsiendil oli gripp, oli pereliikmeid, kellel tekkis gripp, Tamiflud kasutanutest 7% ning platseebot saanutest 20%.
English: In the study carried out during an epidemic, 1% of the people taking Tamiflu developed flu after contact, compared with 5% of those taking placebo.
Estonian: Epideemia ajal tehtud uuringus oli isikuid, kellel tekkis pärast kokkupuudet gripp, Tamiflud kasutanutest 1% ning platseebot saanutest 5%.
English: The most common side effects with Tamiflu (seen in more than 1 patient in 10) in adults and adolescents are headache and nausea (feeling sick).
Estonian: Tamiflu kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on peavalu ja iiveldus.
English: What benefits of Tamiflu have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Tamiflu kasulikkus?
English: In children the most common side effects (seen in more than 1 patient in 10) are vomiting, cough and nasal congestion (a blocked nose).
Estonian: Lastel on kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) oksendamine, köha ja ninakinnisus.
English: • to prevent flu, it can be used in adults and children over 1 year of age who have been in contact with someone who has flu and flu is circulating in the community.
Estonian: • Gripi ennetamiseks tohib ravimit kasutada täiskasvanutel ja vähemalt 1-aastastel gripipatsiendiga kokku puutunud lastel, kui kogukonnas levib gripiviirus.
English: Treatment of flu
Estonian: Gripi ravi
English: Tamiflu reduced the duration of the illness compared with placebo (a dummy treatment) in several studies (involving 2,413 patients aged 13 years or over, 741 elderly patients aged 65 years or over and 1,033 children aged between 1 and 12 years).
Estonian: Mitmes uuringus (kokku osales 2413 vähemalt 13-aastast patsienti, 741 vähemalt 65-aastast eakat patsienti ja 1033 last vanuses 1-12 aastat) vähendas Tamiflu platseeboga (näiv ravim) võrreldes haiguse kestust.
English: How is Tamiflu used?
Estonian: Kuidas Tamiflud kasutatakse?
English: In the prevention of flu, Tamiflu must be started within two days of contact with someone who has flu.
Estonian: Gripi ennetamisel peab Tamiflu kasutamist alustama 2 ööpäeva jooksul alates kokkupuutest gripipatsiendiga.
English: An overview of Tamiflu and why it is authorised in the EU
Estonian: Ülevaade ravimist Tamiflu ja ELis müügiloa väljastamise põhjendus
English: The medicine can only be obtained with a prescription.
Estonian: Tamiflu on retseptiravim.
English: What measures are being taken to ensure the safe and effective use of Aimovig?
Estonian: Mis meetmed võetakse, et tagada Aimovigi ohutu ja efektiivne kasutamine?
English: Patients can inject the medicine themselves after being trained.
Estonian: Patsiendid tohivad ravimit pärast väljaõppe saamist ise süstida.
English: Aimovig received a marketing authorisation valid throughout the EU on 26 July 2018.
Estonian: Aimovig on saanud müügiloa, mis kehtib kogu ELis, 26. juulil 2018.
English: Further information on Aimovig can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/aimovig.
Estonian: Lisateave Aimovigi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/aimovig.
English: Aimovig (erenumab)
Estonian: Aimovig (erenumaab)
English: EMA/CHMP/249688/2019 EMEA/H/C/004447
Estonian: EMA/191978/2019 EMEA/H/C/004447
English: Most of the side effects are mild or moderate in severity.
Estonian: Enamik kõrvalnähtudest on kerge või mõõduka raskusastmega.
English: The European Medicines Agency therefore decided that Aimovig's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas seetõttu, et Aimovigi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib Euroopa Liidus heaks kiita.
English: What is Aimovig and what is it used for?
Estonian: Mis on Aimovig ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Aimovig are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Aimovigi kasutamise kohta pidevat järelevalvet.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Aimovig have been included in the summary of product characteristics and the package leaflet.
Estonian: Aimovigi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Some patients may benefit from a dose of 140 mg every 4 weeks, given as either a single injection of 140 mg or two injections of 70 mg.
Estonian: Mõnel patsiendil võib kasu olla 140 mg annusest iga 4 nädala järel kas ühekordse süstena (140 mg) või kahe süstena (kumbki 70 mg).
English: The most common side effects with Aimovig (which may affect up to 1 in 10 people) are reactions at the site of injection, constipation, muscle spasms and itching.
Estonian: Aimovigi kõige sagedamad kõrvalnähud (võivad esineda kuni 1 patsiendil 10st) on süstekoha reaktsioonid, kõhukinnisus, lihasespasmid ja sügelus.
English: Side effects reported with Aimovig are carefully evaluated and any necessary action taken to protect patients.
Estonian: Aimovigi kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: For more information about using Aimovig, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Aimovigi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Aimovig is a medicine used to prevent migraine in adults who have migraines at least 4 days a month.
Estonian: Aimovig on ravim, mida kasutatakse migreeni ennetamiseks täiskasvanutel, kellel on vähemalt 4 migreenipäeva kuus.
English: The recommended dose is 70 mg every 4 weeks as a single injection.
Estonian: Soovitatav annus on 70 mg iga 4 nädala järel ühekordse süstena.
English: For the full list of side effects and restrictions of Aimovig, see the package leaflet.
Estonian: Aimovigi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: By attaching to this receptor, the medicine stops CGRP from attaching to it and causing migraine.
Estonian: Selle retseptoriga seondudes ei lase ravim CGRP-l retseptoriga seonduda ja migreeni põhjustada.
English: Only patients with migraines at least 4 days a month were included in the studies as patients with less frequent migraines are not usually eligible for preventative treatment.
Estonian: Uuringutes osalesid üksnes patsiendid, kellel oli kuus vähemalt 4 migreenipäeva, sest harvem esineva migreeniga patsientidel ei ole ennetav ravi enamasti näidustatud.
English: Aimovig (erenumab) EMA/CHMP/249688/2019
Estonian: Aimovig (erenumaab) EMA/191978/2019
English: Aimovig is injected under the skin using a pre-filled syringe or pen.
Estonian: Aimovigi süstitakse naha alla eeltäidetud süstla või pensüstliga.
English: In a second study of 955 patients who had migraines 8 days a month on average, those treated with Aimovig had on average 3 to 4 fewer days with migraines per month compared with around 2 fewer days for patients on placebo.
Estonian: Teises uuringus, milles osales 955 patsienti, kellel oli kuus keskmiselt 8 migreenipäeva, vähenes migreenipäevade arv Aimovigi kasutanud patsientidel keskmiselt 3-4 päeva võrra ning platseebot kasutanud patsientidel ligikaudu 2 päeva võrra.
English: The active substance in Aimovig, erenumab, is a monoclonal antibody (a type of protein) designed to attach to a receptor (target) for CGRP on body's cells.
Estonian: Aimovigi toimeaine erenumaab on monoklonaalne antikeha (teatud valk), mis seondub CGRP retseptoriga (sihtmärk) organismi rakkudel.
English: In a study of 667 patients who had migraines 18 days a month on average, those treated with Aimovig had 7 fewer days with migraines per month, compared with 4 fewer days for patients on placebo.
Estonian: Uuringus, milles osales 667 patsienti, kellel oli kuus keskmiselt 18 migreenipäeva, vähenes migreenipäevade arv Aimovigi kasutanud patsientidel 7 päeva võrra ning platseebot kasutanud patsientidel 4 päeva võrra.
English: Aimovig was shown to be effective at reducing the number of days patients have migraines.
Estonian: Aimovig on olnud tõendatult efektiivne patsientide migreenipäevade arvu vähendamisel.
English: Aimovig contains the active substance erenumab.
Estonian: Aimovig sisaldab toimeainena erenumaabi.
English: What are the risks associated with Aimovig?
Estonian: Mis riskid Aimovigiga kaasnevad?
English: How is Aimovig used?
Estonian: Kuidas Aimovigi kasutatakse?
English: An overview of Aimovig and why it is authorised in the EU
Estonian: Ülevaade ravimist Aimovig ja ELis müügiloa väljastamise põhjendus
English: Aimovig is effective at reducing the number of days patients suffer migraines.
Estonian: Aimovig on efektiivne patsientide migreenipäevade arvu vähendamisel.
English: Aimovig can only be obtained with a prescription and treatment should be started by a doctor experienced in the diagnosis and treatment of migraine.
Estonian: Ravi sellega peab alustama migreeni diagnoosimises ja ravis kogenud arst.
English: A chemical messenger called CGRP has been shown to be involved in the development of migraine.
Estonian: On tõendatud, et migreeni tekkes osaleb virgatsaine CGRP (kaltsitoniini geeniga seotud peptiid).
English: Other information about Aimovig
Estonian: Muu teave Aimovigi kohta
English: What benefits of Aimovig have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Aimovigi kasulikkus?
English: Each cycle lasts 21 days.
Estonian: Iga tsükkel kestab 21 päeva.
English: Other medicines and Polivy
Estonian: Muud ravimid ja Polivy
English: This is because Polivy can affect your baby's health.
Estonian: See on vajalik sellepärast, et Polivy võib mõjutada teie lapse tervist.
English: PET-CT PR required meeting both PET-CT criteria and CT criteria.
Estonian: PET-CT PR pidi vastama nii PET-CT kriteeriumidele kui ka CT kriteeriumidele.
English: Reactivation of latent infections has been reported.
Estonian: Teatatud on latentsete infektsioonide reaktiveerumisest.
English: 80% of patients had refractory disease.
Estonian: 80%-l patsientidest oli refraktaarne haigus.
English: A risk for breast-feeding children cannot be excluded.
Estonian: Riski rinnaga toidetavatele lastele ei saa välistada.
English: Polivy can cause IRRs , including severe cases.
Estonian: Polivy võib põhjustada IRR-e, kaasa arvatud rasked juhud.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/19/1388/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/19/1388/001
English: Active severe infections (see section 4.4).
Estonian: Aktiivsed rasked infektsioonid (vt lõik 4.4).
English: These may be new symptoms or a change in your current symptoms.
Estonian: Tegemist võib olla uute sümptomite või olemasolevate sümptomite muutusega:
English: Give supportive treatment.
Estonian: Alustada toetavat ravi.
English: Pay attention to the following side effects
Estonian: Pöörake tähelepanu järgmistele kõrvaltoimetele
English: Prophylactic granulocyte colony stimulating factor (G-CSF) administration was required in the clinical development and should be considered.
Estonian: Profülaktiline granulotsüütide kolooniat stimuleeriva faktori (G-CSF) manustamine oli vajalik kliinilise arenduse käigus ja seda tuleb kaaluda.
English: • unusual sensations
Estonian: • ebatavalised aistingud.
English: This being a conditional marketing authorisation and pursuant to Article 14-a(4) of Regulation (EC) No 726/2004, the MAH shall complete, within the stated timeframe, the following measures:
Estonian: Tingimusliku müügiloaga ja vastavalt EÜ määruse nr 726/2004 artiklile 14-a (4) rakendab müügiloa hoidja ettenähtud aja jooksul järgmisi meetmeid:
English: The median age was 69 years (range: 30-86 years).
Estonian: Vanuse mediaan oli 69 aastat (vahemik: 30...86 aastat).
English: • discomfort or weakness.
Estonian: • ebamugavustunne või nõrkus.
English: Each pack of Polivy consists of one vial.
Estonian: Iga Polivy pakend sisaldab ühte viaali.
English: The majority of patients (98%) had DLBCL not otherwise specified (NOS).
Estonian: Enamikel patsientidel (98%) oli teisiti täpsustamata (not otherwise specified, NOS) DLBCL.
English: Sodium chloride 9 mg/mL (0.9%)
Estonian: Naatriumkloriid 9 mg/ml (0,9%)
English: • you think you have an infection or have had long-lasting or repeated infections such as herpes (see “Infections” in section 4).
Estonian: • kui arvate, et teil on infektsioon või kui teil on esinenud kauakestvaid või korduvaid infektsioone, nagu herpes (vt „Infektsioonid“ lõigus 4).
English: • you have ever had liver problems
Estonian: • kui teil on kunagi olnud probleeme maksaga.
English: The safety and efficacy in children and adolescents less than 18 years have not been established.
Estonian: Polivy ohutus ja efektiivsus lastel ja noorukitel vanuses kuni 18 aastat ei ole tõestatud.
English: Polivy will be stored by the healthcare professionals at the hospital or clinic.
Estonian: Polivy'd säilitavad tervishoiutöötajad haiglas või kliinikus.
English: For the clinical development program of Polivy as a whole, an estimated total of 588 patients have received Polivy.
Estonian: Polivy kliinilises arendusprogrammis tervikuna on hinnanguliselt ravimit saanud kokku 588 patsienti.
English: This patient had three prior lines of therapy that included anti-CD20 antibodies.
Estonian: See patsient oli saanud kolme eelnevat raviskeemi, mille hulka kuulusid CD20 vastased antikehad.
English: These are a type of blood cells.
Estonian: Need on teatud tüüpi vererakud.
English: Human Immunodeficiency Virus (HIV)
Estonian: Inimese immuunpuudulikkuse viirus (HIV)
English: You should not use this medicine if you are pregnant unless you and your doctor decide that the benefit to you outweighs possible risk to the unborn baby.
Estonian: Te ei tohi seda ravimit kasutada raseduse ajal, välja arvatud juhul, kui teie ja arst otsustate, et ravist saadav kasu ületab võimalikud ohud veel sündimata lapsele.
English: • you are due to have a vaccine or you know you may need to have one in the near future
Estonian: • kui teil on käes mõne vaktsiini manustamise aeg või te teate, et vajate lähiajal mõnda vaktsiini.
English: MMAE does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6.
Estonian: MMAE ei inhibeeri CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 ega CYP2D6.
English: The dose of this medicine depends on your body weight.
Estonian: Ravimi annus sõltub teie kehakaalust.
English: However, motor and sensorimotor PN have also been reported.
Estonian: Kuid kirjeldatud on ka motoorset ja sensomotoorset PN-i.
English: If you had any of these symptoms before treatment with Polivy, tell your doctor straight away if you notice any changes in them.
Estonian: Kui teil esines mõni neist sümptomitest enne ravi Polivy'ga, teavitage oma arsti otsekohe sellest, kui märkate nende sümptomite muutust.
English: If you get any serious reaction, your doctor may stop treatment with Polivy.
Estonian: Mis tahes tõsise reaktsiooni tekkimisel võib teie arst lõpetada ravi Polivy'ga.
English: Follow applicable proper handling and disposal procedure (see section 6.6).
Estonian: Järgige nõuetekohast käsitsemise ja hävitamise protseduuri (vt lõik 6.6)
English: For the treatment to be fully effective, it is very important not to miss a dose.
Estonian: Et ravi oleks tõhus, on väga tähtis, et ükski annus ei jääks manustamata.
English: Contraception (women and men)
Estonian: Rasestumisvastane kaitse (naised ja mehed)
English: Lonzastrasse CH-3930 Visp Switzerland
Estonian: Lonzastrasse CH-3930 Visp Šveits
English: Bendamustine + rituximab N = 40 Median observation time 22 months
Estonian: Bendamustiin + rituksimab N = 40 Jälgimisaja mediaan 22 kuud
English: In order to improve traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded.
Estonian: Bioloogiliste ravimpreparaatide jälgitavuse parandamiseks tuleb manustatava ravimi nimi ja partii number selgelt dokumenteerida.
English: The ADRs are listed below by MedDRA system organ class (SOC) and categories of frequency.
Estonian: Järgnevalt on kõrvaltoimed loetletud MedDRA organsüsteemi klassi (system organ class, SOC) ja esinemissageduse kategooriate järgi.
English: IRC: Independent Review Committee; INV: Investigator; HR: Hazard Ratio; CI: Confidence Interval, NE: Not evaluable; CMH Cochran-Mantel-Haenszel *Per modified Lugano 2014 criteria: Bone marrow confirmation of PET-CT CR required.
Estonian: IRC: sõltumatu hindamiskogu; INV: uurija; HR: riskitiheduste suhe; CI: usaldusvahemik, NE: mittehinnatav; CMH: Cochran-Mantel-Haenszel *Vastavalt modifitseeritud Lugano 2014 kriteeriumidele: vajalik oli PET-CT CR-i luuüdi kinnitus.